Several peptide therapeutics are used as replacement therapies in order to supplement peptide hormones when endogenous levels are inadequate or absent. Insulin and adrenocorticotrophic hormone (ACTH) are peptides isolated from natural sources, whereas oxytocin and vasopressin are synthetic peptides.
The global peptide therapeutics market is estimated to account for US$ 23,319.3 Mn in terms of value and is expected to reach US$ 57,166.5 Mn by the end of 2027.
Global Peptide Therapeutics Market: Drivers
Increasing adoption of peptide therapeutics is expected to aid in growth of the global peptide therapeutics market over the forecast period. Peptides therapeutics are typically associated with lower production complexity compared with protein-based-biopharmaceuticals. This in turn results in lower production costs, which increases adoption of peptides therapeutics compared to small molecules and biopharmaceuticals.
Global Peptide Therapeutics Market: Opportunities
Development of multifunctional peptides and conjugates is expected to offer lucrative growth opportunities for players in the market. For instance, in February 2019, researchers from University of Milan reported that the polypeptide lunasin derived from bioactive food offered hypocholesterolemic, antioxidant, and anti-inflammatory properties and can be effective in prevention of cardiovascular disease.
Global Peptide Therapeutics Market: Restraints
Therapeutic peptides have low membrane permeability and are prone to hydrolysis and oxidation, which is expected to hinder growth of the market.
The branded sub segment in the product type segment in global peptide therapeutics market was valued at US$ 12,415.2 Mn in 2018 and is expected to reach US$ 27,349.8 Mn by 2027 at a CAGR of 9.1% during the forecast period.
Branded medications in the peptide therapeutics market have extensive patent protections and preferred by the physicians in developed as well as emerging economies. Moreover, branded medications are costly as compared to generic peptide therapeutics.
The cancer sub segment in applications segment held dominant position in the global peptide therapeutics market in 2018, accounting for 34.3% share in terms of value, followed by metabolic disorders and central nervous system disorders, respectively.
Increasing prevalence of cancer is expected to create lucrative opportunities for growth of manufacturers in the market. For instance, according to the National Cancer Institute, 2016, the number of new cancer cases per year is expected to increase to 23.6 million by 2030, worldwide.
The parenteral sub segment in route of administration segment held dominant position in the global peptide therapeutics market in 20148, accounting for 70.4% share in terms of value, followed by transdermal route and mucosal route, respectively.
Vast number of parenteral peptide therapeutics have been launched in the market. These drugs are effective as the drug is directly administered in the blood stream bypassing gastrointestinal tract.
The market is witnessing increasing adoption of peptide therapeutics for the treatment of cancer. For instance, in January 2020, IBicycle Therapeutics plc., a biotechnology that develops therapeutics based on its proprietary bicyclic peptide technology, collaborated with Cancer Research UK for funding in R&D of BT7401, a multivalent Bicycle CD137 agonist for the treatment of cancer.
Major players in the market are focused on collaborating with universities for R&D of new peptide therapeutics. For instance, in 2018, Sapience Therapeutics, Inc., a biotechnology company focused on R&D in peptide therapeutics, collaborated with the University of Bath to discover new therapeutic agents.
Global Peptide Therapeutics Market: Competitive Landscape
Major players operating in the global peptide therapeutics market include, AstraZeneca plc., Bachem Holding AG, CordenPharma International, Eli Lilly and Company, Ipsen S.A, Merck & Co., Inc., Novo Nordisk A/S, PolyPeptide Group, and Teva Pharmaceutical Industries Ltd.
Global Peptide Therapeutics Market: Key Developments
January 2020: Cybrexa Therapeutics, a privately-held biotechnology company focused on development of next-generation tumor-targeted cancer therapies, announced CBX-12 (alphalex exatecan) as the new lead development program. The Cybrexa alphalex technology platform consists of a pHLIP peptide, linker, and small molecule anti-cancer agent.
January 2020: Protagonist Therapeutics, Inc. announced the achievement of a research milestone under its worldwide license and research collaboration agreement with Janssen Biotech, Inc., for co-development and commercialization of PTG-200, an oral, gut-restricted IL-23 receptor antagonist and second generation peptides for the treatment of inflammatory bowel disease.